A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. (Q44988872)

8 December 2017

title

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. (English)

1 reference

8 December 2017

1 reference

Zeuzem S

1

1 reference

8 December 2017

Hopf U

2

1 reference

8 December 2017

Carreno V

3

1 reference

8 December 2017

Diago M

4

1 reference

8 December 2017

Shiffman M

5

1 reference

8 December 2017

Grüne S

6

1 reference

8 December 2017

Dudley FJ

7

1 reference

8 December 2017

Rakhit A

8

1 reference

8 December 2017

Rittweger K

9

1 reference

8 December 2017

Yap SH

10

1 reference

8 December 2017

Koff RS

11

1 reference

8 December 2017

Thomas HC

12

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

8 December 2017

1 reference

8 December 2017

volume

29

1 reference

8 December 2017

issue

4

1 reference

8 December 2017

page(s)

1280-1287

1 reference

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Hepatitis C virus six years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Therapy of hepatitis C: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

IL-12: initiation cytokine for cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

IL12 receptors and receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

7 January 2021

Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

7 January 2021

The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

7 January 2021

IL-12 deaths: explanation and a puzzle

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

7 January 2021

Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290429

7 January 2021

Identifiers

DOI

10.1002/HEP.510290429

1 reference

8 December 2017

1 reference